As­traZeneca's Fasen­ra ex­pands ap­proval in chil­dren with se­vere asth­ma

As­traZeneca’s asth­ma treat­ment Fasen­ra will now be avail­able to younger pa­tients, height­en­ing the com­pe­ti­tion in a crowd­ed field of res­pi­ra­to­ry ri­vals.

The FDA has ex­pand­ed Fasen­ra’s la­bel to in­clude the add-on main­te­nance treat­ment of chil­dren 6 to 11 years old with se­vere eosinophilic asth­ma. The drug was first ap­proved in the 12-years-and-old­er set­ting in 2017.

Fasen­ra is one of a hand­ful of bi­o­log­ics on the US mar­ket to treat se­vere asth­ma, in­clud­ing GSK’s Nu­cala, which beat As­traZeneca to the 6-and-old­er pop­u­la­tion with a la­bel ex­pan­sion in 2019.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER